Best for
All-rounder
How to buy Johnson & Johnson shares | $144
Own Johnson & Johnson shares in just a few minutes. Share price changes are updated daily.
Fact checked
Johnson & Johnson (JNJ) is a leading drug manufacturers—general business based in the US. It opened the day at $144.5 after a previous close of $143.68. During the day the price has varied from a low of $143.22 to a high of $144.6583. The latest price was $144 (25 minute delay). Johnson & Johnson is listed on the NYSE and employs 132,200 staff. All prices are listed in US Dollars.
How to buy shares in Johnson & Johnson
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: JNJ in this case.
- Research Johnson & Johnson shares. The platform should provide the latest information available.
- Buy your Johnson & Johnson shares. It's that simple.
Best for
Low-cost trading
Best for
US shares
Best for
Beginners
What's in this guide?
- Can I buy shares in Johnson & Johnson?
- Has coronavirus impacted Johnson & Johnson shares?
- Johnson & Johnson shares summary
- Compare share dealing platforms
- Is Johnson & Johnson stock a buy or sell?
- Johnson & Johnson performance over time
- Can I short Johnson & Johnson shares?
- Is Johnson & Johnson suitable for ethical investing?
- Are Johnson & Johnson shares over-valued?
- Johnson & Johnson's financials
- How volatile are Johnson & Johnson shares?
- Does Johnson & Johnson pay a dividend?
- Have Johnson & Johnson shares ever split?
- Other common questions
How has Coronavirus impacted Johnson & Johnson's share price?
Since the stock market crash in March caused by coronavirus, Johnson & Johnson's share price has had significant negative movement.
Its last market close was $148.1, which is 1.22% down on its pre-crash value of $149.93 and 35.67% up on the lowest point reached during the March crash when the shares fell as low as $109.16.
If you had bought $1,000 worth of Johnson & Johnson shares at the start of February 2020, those shares would have been worth $740.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $986.35.
Johnson & Johnson share price
Use our graph to track the performance of JNJ stocks over time.Johnson & Johnson shares at a glance
Information last updated 2020-11-27.
| Open | $144.5 |
|---|---|
| High | $144.6583 |
| Low | $143.22 |
| Close | $144 |
| Previous close | $143.68 |
| Change | $0.32 |
| Change % | 0.223% |
| Volume | 2,992,644 |
Information last updated 2020-11-23.
| 52-week range | $106.9486 - $154.3971 |
|---|---|
| 50-day moving average | $145.3929 |
| 200-day moving average | $146.5855 |
| Wall St. target price | $166.18 |
| PE ratio | 23.0126 |
| Dividend yield | $4.04 (2.76%) |
| Earnings per share (TTM) | $6.36 |
Invest in Johnson & Johnson shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.
Is it a good time to buy Johnson & Johnson stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Johnson & Johnson price performance over time
Historical closes compared with the last close of $144
| 1 week (2020-11-19) | -2.13% |
|---|---|
| 1 month (2020-10-29) | 4.96% |
| 3 months (2020-08-28) | -6.27% |
| 6 months (2020-05-29) | -3.19% |
| 1 year (2019-11-29) | 4.73% |
|---|---|
| 2 years (2018-11-29) | -1.27% |
| 3 years (2017-11-29) | 3.00% |
| 5 years (2015-11-27) | 40.67% |
Is Johnson & Johnson under- or over-valued?
Valuing Johnson & Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson & Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson & Johnson's P/E ratio
Johnson & Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Johnson & Johnson shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Johnson & Johnson's P/E ratio is best considered in relation to those of others within the drug manufacturers—general industry or those of similar companies.
- Pfizer (PFE.US): 23.43
- Gilead Sciences (GILD.US): 61.34
- Abbott Laboratories (ABT.US): 59.04
- IDEXX Laboratories (IDXX.US): 80.10
- GlaxoSmithKline (GSK.LSE): 10.61
- AstraZeneca (AZN.LSE): 57.99
Johnson & Johnson's PEG ratio
Johnson & Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.7211. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson & Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Johnson & Johnson's PEG ratio in relation to those of similar companies.
- Pfizer (PFE.US): 5.19
- Gilead Sciences (GILD.US): 0.44
- Abbott Laboratories (ABT.US): 3.49
- IDEXX Laboratories (IDXX.US): 6.22
- GlaxoSmithKline (GSK.LSE): 7.34
- AstraZeneca (AZN.LSE): 1.28
Johnson & Johnson's EBITDA
Johnson & Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $27.3 billion (£20.4 billion).
The EBITDA is a measure of a Johnson & Johnson's overall financial performance and is widely used to measure a its profitability.
To put Johnson & Johnson's EBITDA into context you can compare it against that of similar companies.
- Pfizer (PFE.US): USD$19.3 billion
- Gilead Sciences (GILD.US): USD$6.3 billion
- Abbott Laboratories (ABT.US): USD$7.8 billion
- IDEXX Laboratories (IDXX.US): USD$698.2 million
- GlaxoSmithKline (GSK.LSE): £9.1 billion
- AstraZeneca (AZN.LSE): £7.7 billion
Johnson & Johnson financials
| Revenue TTM | $80.9 billion |
|---|---|
| Operating margin TTM | 24.93% |
| Gross profit TTM | $54.6 billion |
| Return on assets TTM | 7.72% |
| Return on equity TTM | 27.69% |
| Profit margin | 21.01% |
| Book value | $24.494 |
| Market capitalisation | $385.3 billion |
TTM: trailing 12 months
How to short and sell Johnson & Johnson shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "JNJ.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 12.8 million Johnson & Johnson shares held short by investors – that's known as Johnson & Johnson's "short interest". This figure is 11.5% up from 11.5 million last month.
There are a few different ways that this level of interest in shorting Johnson & Johnson shares can be evaluated.
Johnson & Johnson's "short interest ratio" (SIR)
Johnson & Johnson's "short interest ratio" (SIR) is the quantity of Johnson & Johnson shares currently shorted divided by the average quantity of Johnson & Johnson shares traded daily (recently around 6.3 million). Johnson & Johnson's SIR currently stands at 2.02. In other words for every 100,000 Johnson & Johnson shares traded daily on the market, roughly 2020 shares are currently held short.
To gain some more context, you can compare Johnson & Johnson's short interest ratio against those of similar companies.
- Pfizer (PFE.US): 1.93
- Gilead Sciences (GILD.US): 2.18
- Abbott Laboratories (ABT.US): 2.28
- IDEXX Laboratories (IDXX.US): 2.68
However Johnson & Johnson's short interest can also be evaluated against the total number of tradable Johnson & Johnson shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson & Johnson's short interest could be expressed as 0.0049% of the tradable shares (for every 100,000 tradable Johnson & Johnson shares, roughly 5 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Johnson & Johnson.
Find out more about how you can short Johnson & Johnson stock.
Johnson & Johnson's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson & Johnson.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Johnson & Johnson's total ESG risk score
Total ESG risk: 35.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson & Johnson's overall score of 35.8 (as at 01/01/2019) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson & Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Johnson & Johnson's total ESG risk score against those of similar companies.
- Pfizer (PFE.US): 33.15
- Gilead Sciences (GILD.US): 22.15
- Abbott Laboratories (ABT.US): 32.35
- IDEXX Laboratories (IDXX.US): 29.79
- GlaxoSmithKline (GSK.LSE): 28.51
- AstraZeneca (AZN.LSE): 28.52
Johnson & Johnson's environmental score
Environmental score: 3.79/100
Johnson & Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Johnson & Johnson's social score
Social score: 25.14/100
Johnson & Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Johnson & Johnson's governance score
Governance score: 14.87/100
Johnson & Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson & Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Johnson & Johnson's controversy score
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Johnson & Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson & Johnson has a damaged public profile.
Wondering how that compares? Below are the controversy scores of similar companies.
- Pfizer (PFE.US): 3
- Gilead Sciences (GILD.US): 2
- Abbott Laboratories (ABT.US): 3
- GlaxoSmithKline (GSK.LSE): 3
- AstraZeneca (AZN.LSE): 3
Environmental, social, and governance (ESG) summary
Johnson & Johnson was last rated for ESG on: 2019-01-01.
| Total ESG score | 35.8 |
|---|---|
| Total ESG percentile | 72.38 |
| Environmental score | 3.79 |
| Environmental score percentile | 7 |
| Social score | 25.14 |
| Social score percentile | 7 |
| Governance score | 14.87 |
| Governance score percentile | 7 |
| Level of controversy | 4 |
Johnson & Johnson share dividends
Dividend payout ratio: 49.44% of net profits
Recently Johnson & Johnson has paid out, on average, around 49.44% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.76% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson & Johnson shareholders could enjoy a 2.76% return on their shares, in the form of dividend payments. In Johnson & Johnson's case, that would currently equate to about $4.04 per share.
While Johnson & Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson & Johnson may be investing much of the rest of its net profits in future growth.
Johnson & Johnson's most recent dividend payout was on 8 December 2020. The latest dividend was paid out to all shareholders who bought their shares by 23 November 2020 (the "ex-dividend date").
Johnson & Johnson's dividend payout ratio is perhaps best considered in relation to those of similar companies.
- Pfizer (PFE.US): 53.33%
- Gilead Sciences (GILD.US): 43.87%
- Abbott Laboratories (ABT.US): 45.71%
- IDEXX Laboratories (IDXX.US): 0.00% (does not pay dividend)
- GlaxoSmithKline (GSK.LSE): 6,611.57%
- AstraZeneca (AZN.LSE): 6,945.34%
Have Johnson & Johnson's shares ever split?
Johnson & Johnson's shares were split on a 2:1 basis on 13 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson & Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson & Johnson shares which in turn could have impacted Johnson & Johnson's share price.
Johnson & Johnson share price volatility
Over the last 12 months, Johnson & Johnson's shares have ranged in value from as little as $106.9486 up to $154.3971. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson & Johnson's is 0.6911. This would suggest that Johnson & Johnson's shares are less volatile than average (for this exchange).
To put Johnson & Johnson's beta into context you can compare it against those of similar companies.
- Pfizer (PFE.US): 0.6415
- Gilead Sciences (GILD.US): 0.5451
- Abbott Laboratories (ABT.US): 0.8935
- IDEXX Laboratories (IDXX.US): 0.8103
- GlaxoSmithKline (GSK.LSE): 0.3411
- AstraZeneca (AZN.LSE): 0.2994
Win £500 to get your trading started
Subscribe to trending stock alerts for a chance to win
Johnson & Johnson overview
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Frequently asked questions
More guides on Finder
-
How to buy Johnson & Johnson shares
Ever wondered how to invest in HMCX ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
-
How to buy Johnson & Johnson shares
Ever wondered how to invest in CRUD ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
-
How to buy Johnson & Johnson shares
Ever wondered how to invest in XUKX ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
-
How to buy iShares Physical Gold ETC shares | 2651.5p
Ever wondered how to invest in SGLN ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
-
How to buy Gold Bullion Securities ETC shares
Ever wondered how to invest in GBSS ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
-
How to buy Johnson & Johnson shares
Ever wondered how to invest in CUK ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
-
How to buy Johnson & Johnson shares
Ever wondered how to invest in LGJG ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
-
How to buy Johnson & Johnson shares
Ever wondered how to invest in SJPA ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
-
How to buy Johnson & Johnson shares
Ever wondered how to invest in LCJG ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
-
How to buy Johnson & Johnson shares
Ever wondered how to invest in SAWD ETF? Learn more about it now and find out where you can invest in it. Compare ETF brokers to start investing today.
Ask an Expert